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In recent decades, the industrialized world
has seen a dramatic decline in the morbidity and
mortality associated with cardiovascular disease.
Unfortunately, this benefit from preventative
therapies and medical technologies has not been
witnessed in low- and middle-income countries
(LMIC) that account for >80% of all cardiovascu-
lar deaths worldwide.1 What was once thought to
be a disease of only affluent industrialized nations
has now superseded malaria and tuberculosis as
the epidemic of the 21st century.
There exists no greater inequality between
industrialized nations and LMIC than in the field
of cardiac electrophysiology—specifically device
implantation. In 2005 alone, more than 1,050 new
pacemakers and implantable defibrillators (ICDs)
were implanted per million people in the United
States as compared to 111 new cardiac device
implants per million people in Brazil.2 As a result
of these gross inequalities, various organizations
have recently delivered cardiac devices to those
in need in underserved nations: (1) Heartbeat
International is a charitable organization that
specializes in allocating pacemakers near their
“sell-by” date generously donated by device man-
ufacturers. To date, more than 9,000 devices have
been implanted through pacemaker banks estab-
lished by local Rotary International chapters in 24
countries over four continents.3 (2) World Medical
Relief, a nonprofit organization specializing in
delivery of medical equipment for distribution
to hospitals and clinics in underserved nations,
recently delivered 12 resterilized pacemakers
to patients in the Philippines who could not
afford device therapy.4 Novel therapies must be
considered in order to prevent the estimated
one million deaths that occur annually due to
a lack of access to bradyarrhythmia therapy.5
Device reutilization appears to be a safe, feasible,
and ethically responsible means of delivering
electrophysiological healthcare to those in great
need in underserved nations.
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In this issue of the Journal, Hasan et al.6
extend prior observations of device reutilization
for those who are unable to acquire brady-
or tachyarrhythmia therapy. These investigators
acquired antemortem cardiac rhythm devices with
≥70% battery from 17 patients who met criteria
for device explantation. The majority of devices
were harvested as a result of necessary upgrade;
however, seven devices utilized in the study
were explanted due to infection. The devices
then underwent a superficial cleansing procedure
followed by an ethylene oxide protocol. The pace-
makers and ICDs were then transported to Centro
de Cardiology Nacional and Hospital Militar de
Managua in Nicaragua. Patients who were deemed
financially incapable of acquiring a new device
were then offered a resterilized device. At 68 ±
38 months no patients exhibited signs of infection,
early battery depletion, or device malfunction.
Three patients died secondary to reasons not
attributable to their device. The authors concluded
that antemortem device reutilization is a safe and
effective method of care for those in underserved
nations such as Nicaragua.
So, is device reutilization the panacea for
all those in underserved nations who require
brady- or tachyarrhythmia therapies? Prior to
altruistic electrophysiologists distributing previ-
ously implanted devices around the world for
reutilization, several issues must be addressed.
First, is this practice safe? The authors of this
study would lead us to believe that antemortem
device reutilization is safe, although they were
limited by a small sample size. However, their
observations are supported by a meta-analysis that
examined four trials and 603 patients with reused
devices and found no higher rate of infection when
compared to device implantation.7 Moreover, 5%
of all devices implanted in Sweden in 1996 were
from a previous recipient; there is no evidence
that this practice resulted in any increased patient
risk.8 Larger clinical studies are necessary to
further understand the safety of device reuse from
an infectious disease perspective.
Second, reutilized device allocation is limited
to countries with government-run health facilities
as patients presumably will not be able to afford
physician or hospital fees. Even with government
assistance, the patient would be responsible for
obtaining a new lead ($200); however, we believe
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this is a reasonable expense for most patients
and their families.9,10 Namboodiri et al.11 showed
that dual-chamber pacemaker generators can be
effectively implanted as single VDD lead devices
resulting in a significant cost savings as compared
to the purchase of two new leads, and there was
no difference in quality-of-life scores.
Finally, it is conceivable that the allocation
of $10,000–$25,000 medical devices in an un-
regulated setting could lead to an inadvertent
“black market” resulting in unfair distribution and
diversion away from those who are most likely to
benefit. Aside from medical factors, determining
a hierarchy of “deservedness” in the setting of
extreme scarcity may lead to potential abuse and
self-gain.12 However, one must never deny or limit
medical technology to those less fortunate due to
a possibility of malfeasance, but rather institute
safeguards with meticulous chains of custody,
proper documentation, and credentialing of each
handler. Clear policies for device distribution
must be in place, as well as appropriate channels
for auditing.12
In conclusion, Hasan et al.6 have provided
further evidence that device reutilization can be
performed in a safe and efficacious manner with
excellent outcomes. From a clinical perspective,
the reuse of devices for those in underserved
countries, such as Nicaragua, appears to be a safe
and effective method of providing healthcare to
those with limited options. Large-scale clinical
studies are necessary to further understand
the efficacy and risk of device reutilization in
underserved countries.
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